
AtriCure (ATRC) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
136.1M
Gross Profit
101.5M
74.54%
Operating Income
-6.2M
-4.55%
Net Income
-6.2M
-4.55%
EPS (Diluted)
$-0.13
Balance Sheet Metrics
Total Assets
591.6M
Total Liabilities
137.0M
Shareholders Equity
454.6M
Debt to Equity
0.30
Cash Flow Metrics
Operating Cash Flow
1.5M
Free Cash Flow
-13.2M
Revenue & Profitability Trend
AtriCure Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 465.3M | 399.2M | 330.4M | 274.3M | 206.5M |
Cost of Goods Sold | 117.8M | 98.9M | 84.4M | 68.5M | 57.2M |
Gross Profit | 347.5M | 300.4M | 245.9M | 205.9M | 149.3M |
Gross Margin % | 74.7% | 75.2% | 74.4% | 75.0% | 72.3% |
Operating Expenses | |||||
Research & Development | 96.2M | 73.9M | 57.3M | 48.5M | 43.1M |
Selling, General & Administrative | 291.4M | 253.1M | 231.3M | 204.6M | 150.8M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 387.5M | 327.1M | 288.6M | 253.2M | 193.9M |
Operating Income | -40.0M | -26.7M | -42.7M | -47.3M | -44.6M |
Operating Margin % | -8.6% | -6.7% | -12.9% | -17.2% | -21.6% |
Non-Operating Items | |||||
Interest Income | 4.4M | 3.8M | 2.0M | 466.0K | 1.1M |
Interest Expense | 6.4M | 6.9M | 5.0M | 4.9M | 4.9M |
Other Non-Operating Income | -1.7M | -31.0K | -537.0K | 102.1M | 333.0K |
Pre-tax Income | -43.7M | -29.8M | -46.2M | 50.4M | -48.0M |
Income Tax | 1.0M | 591.0K | 268.0K | 188.0K | 114.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.4% | 0.0% |
Net Income | -44.7M | -30.4M | -46.5M | 50.2M | -48.2M |
Net Margin % | -9.6% | -7.6% | -14.1% | 18.3% | -23.3% |
Key Metrics | |||||
EBITDA | -17.2M | -8.1M | -29.5M | -36.8M | -34.0M |
EPS (Basic) | $-0.95 | $-0.66 | $-1.02 | $1.11 | $-1.14 |
EPS (Diluted) | $-0.95 | $-0.66 | $-1.02 | $1.09 | $-1.14 |
Basic Shares Outstanding | 46965000 | 46309000 | 45740000 | 45066000 | 42125000 |
Diluted Shares Outstanding | 46965000 | 46309000 | 45740000 | 45066000 | 42125000 |
Income Statement Trend
AtriCure Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 122.7M | 84.3M | 58.1M | 43.7M | 41.9M |
Short-term Investments | 0 | 53.0M | 63.0M | 75.4M | 202.3M |
Accounts Receivable | 60.3M | 52.5M | 42.7M | 33.0M | 23.1M |
Inventory | 75.3M | 67.9M | 45.9M | 39.0M | 35.0M |
Other Current Assets | 9.4M | 8.6M | 5.5M | 5.0M | 4.3M |
Total Current Assets | 267.8M | 266.2M | 215.2M | 196.1M | 306.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 31.4M | 27.7M | 25.1M | 24.9M | 21.0M |
Goodwill | 526.0M | 533.5M | 508.9M | 512.6M | 597.8M |
Intangible Assets | 56.5M | 64.0M | 39.3M | 43.0M | 128.2M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 2.9M | 2.2M | 2.0M | 955.0K | 440.0K |
Total Non-Current Assets | 341.5M | 347.7M | 370.2M | 419.2M | 407.8M |
Total Assets | 609.3M | 613.9M | 585.4M | 615.3M | 714.5M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 25.0M | 27.4M | 19.9M | 18.6M | 12.7M |
Short-term Debt | 2.8M | 2.5M | 5.5M | 1.8M | 8.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | 5.5M | 1.8M | - |
Total Current Liabilities | 73.4M | 74.6M | 58.4M | 56.4M | 49.1M |
Non-Current Liabilities | |||||
Long-term Debt | 73.7M | 72.0M | 69.1M | 73.9M | 65.6M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 1.2M | 1.2M | 1.2M | 1.2M | 187.4M |
Total Non-Current Liabilities | 74.9M | 73.2M | 70.3M | 75.1M | 253.0M |
Total Liabilities | 148.4M | 147.8M | 128.7M | 131.6M | 302.1M |
Equity | |||||
Common Stock | 49.0K | 48.0K | 47.0K | 46.0K | 45.0K |
Retained Earnings | -401.8M | -357.1M | -326.6M | -280.2M | -330.4M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 461.0M | 466.2M | 456.8M | 483.8M | 412.4M |
Key Metrics | |||||
Total Debt | 76.5M | 74.5M | 74.5M | 75.6M | 74.0M |
Working Capital | 194.4M | 191.7M | 156.8M | 139.6M | 257.6M |
Balance Sheet Composition
AtriCure Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -44.7M | -30.4M | -46.5M | 50.2M | -48.2M |
Depreciation & Amortization | 18.7M | 14.8M | 11.7M | 10.4M | 9.5M |
Stock-Based Compensation | 40.4M | 35.7M | 28.8M | 28.1M | 22.6M |
Working Capital Changes | -19.6M | -29.8M | -15.9M | -13.1M | -1.7M |
Operating Cash Flow | 9.5M | -7.7M | -20.7M | -106.8M | -16.2M |
Investing Activities | |||||
Capital Expenditures | -11.4M | -12.0M | -16.9M | -9.8M | -5.3M |
Acquisitions | - | - | - | 0 | 0 |
Investment Purchases | 0 | 0 | -24.6M | -173.1M | -227.0M |
Investment Sales | 53.7M | 63.8M | 85.5M | 206.4M | 75.3M |
Investing Cash Flow | 42.2M | 51.8M | 44.0M | 23.5M | -156.2M |
Financing Activities | |||||
Share Repurchases | -7.0M | -6.6M | -12.2M | -18.0M | -13.0M |
Dividends Paid | 0 | - | - | - | - |
Debt Issuance | 61.2M | 0 | 0 | 5.0M | 0 |
Debt Repayment | -62.9M | -992.0K | -899.0K | -5.8M | -667.0K |
Financing Cash Flow | -8.6M | -7.6M | -13.1M | -20.0M | 175.2M |
Free Cash Flow | -11.3M | -37.5M | -39.0M | -23.5M | -25.1M |
Net Change in Cash | 43.2M | 36.5M | 10.3M | -103.3M | 2.8M |
Cash Flow Trend
AtriCure Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-39.39
Forward P/E
-56.71
Price to Book
3.82
Price to Sales
3.55
PEG Ratio
1.67
Profitability Ratios
Profit Margin
-7.27%
Operating Margin
-4.55%
Return on Equity
-7.85%
Return on Assets
-3.53%
Financial Health
Current Ratio
3.94
Debt to Equity
16.63
Beta
1.62
Per Share Data
EPS (TTM)
$-0.77
Book Value per Share
$9.35
Revenue per Share
$10.56
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
atrc | 1.8B | -39.39 | 3.82 | -7.85% | -7.27% | 16.63 |
Intuitive Surgical | 168.4B | 65.35 | 9.44 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 56.4B | 35.95 | 2.21 | 6.18% | 7.41% | 75.93 |
Staar Surgical | 1.4B | 49.73 | 4.07 | -25.55% | -42.45% | 12.04 |
Azenta | 1.4B | -10.24 | 0.82 | -9.15% | -16.68% | 3.15 |
Biolife Solutions | 1.2B | -58.89 | 3.48 | -5.66% | -5.92% | 6.86 |
Financial data is updated regularly. All figures are in the company's reporting currency.